文献速递呼吸道感染

孕期流感疫苗接种:三项随机对照试验的汇总分析

Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials.
PubMed 文献 · Lancet Respir Med · 2020-01-01

结果显示,疫苗对婴儿6月龄内PCR确诊流感的总体效力为35%(95%CI 19-47),对孕妇为50%(95%CI 32-63),且未发现与不良出生结局或婴儿生长异常相关。

要点

  • 孕期接种流感疫苗对婴儿6月龄内PCR确诊流感的效力为35%(95%CI 19-47)。
  • 疫苗对孕妇孕期至产后6个月PCR确诊流感的效力为50%(95%CI 32-63)。
  • 未发现孕期接种流感疫苗与低出生体重、死产、早产或小于胎龄儿相关。

核心结论

  • 孕期流感疫苗接种可降低母婴PCR确诊流感风险,对婴儿的保护随月龄增加而减弱。
  • 疫苗对孕妇在产后期的保护效力高于孕期,且未增加不良出生结局风险。

研究设计与样本

  • 三项随机对照试验的汇总分析,纳入尼泊尔(2011-2014)、马里(2011-2014)和南非(2011-2013)的孕妇。
  • 孕妇随机1:1接种三价灭活流感疫苗或对照(尼泊尔和南非为生理盐水安慰剂,马里为四价脑膜炎球菌结合疫苗)。

主要发现

  • 婴儿6月龄内PCR确诊流感的汇总效力为35%(95%CI 19-47)。
  • 婴儿出生后2月内效力为56%(95%CI 28-73),2-4月为39%(95%CI 11-58),4-6月为19%(95%CI -9-40)。
  • 孕妇孕期至产后6个月PCR确诊流感效力为50%(95%CI 32-63),孕期为42%(95%CI 12-61),产后为60%(95%CI 36-75)。
  • 孕妇29周前接种的效力为30%(95%CI -2-52),29周及以后接种的效力为71%(95%CI 50-83)。
  • 婴儿效力在29周前接种组为34%(95%CI 12-51),29周及以后接种组为35%(95%CI 11-52)。

关键数值与推荐

  • 婴儿6月龄内PCR确诊流感效力35%(95%CI 19-47)。
  • 孕妇孕期至产后6个月PCR确诊流感效力50%(95%CI 32-63)。
  • 未发现孕期接种与低出生体重、死产、早产或小于胎龄儿总体相关。
  • 6月龄时干预组与对照组在体重不足、生长迟缓、消瘦及体重/身长百分位变化方面相似。

临床怎么用

  • 孕期接种流感疫苗可同时保护孕妇和6月龄内婴儿,应纳入孕期免疫规划考量。
  • 对孕妇的保护在产后阶段更明显,对婴儿的保护在出生后前2个月最强。
  • 接种时机可能影响对孕妇的效力估计,29周前接种的效力评估可能因样本量不足而不精确。

局限性

  • 29周前接种组的效力评估可能因样本量不足而统计效能不够。
  • 三项试验地点和对照疫苗不同,可能影响汇总结果的适用性。
  • 婴儿生长评估在各站点随访时间不完全一致(南非24周,尼泊尔和马里去6个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal influenza immunisation can reduce morbidity and mortality associated with influenza infection in pregnant women and young infants. We aimed to determine the vaccine efficacy of maternal influenza immunisation against maternal and infant PCR-confirmed influenza, duration of protection, and the effect of gestational age at vaccination on vaccine efficacy, birth outcomes, and infant growth up to 6 months of age. METHODS: We did a pooled analysis of three randomised controlled trials done in Nepal (2011-2014), Mali (2011-2014), and South Africa (2011-2013). Pregnant women, gestational age 17-34 weeks in Nepal, 28 weeks or more in Mali, and 20-36 weeks in South Africa, were enrolled. Women were randomly assigned 1:1 to a study group, in which they received trivalent inactivated influenza vaccine (IIV) in all three trials, or a control group, in which they received saline placebo in Nepal and South Africa or quadrivalent meningococcal conjugate vaccine in Mali. Enrolment at all sites was complete by April 24, 2013. Infants and women were assessed for respiratory illness, and samples from those that met the case definition were tested for influenza by PCR testing. Growth measurements, including length and weight, were obtained at birth at all sites, at 24 weeks in South Africa, and at 6 months in Nepal and Mali. The three trials are registered with ClinicalTrials.gov, numbers NCT01430689, NCT01034254, and NCT02465190. FINDINGS: 10 002 women and 9800 liveborn infants were included. Pooled efficacy of maternal vaccination to prevent infant PCR-confirmed influenza up to 6 months of age was 35% (95% CI 19 to 47). The pooled estimate was 56% (28 to 73) within the first 2 months of life, 39% (11 to 58) between 2 and 4 months, and 19% (-9 to 40) between 4 and 6 months. In women, from enrolment during pregnancy to the end of follow-up at 6 months postpartum, the vaccine was 50% (95% CI 32-63) efficacious against PCR-confirmed influenza. Efficacy was 42% (12 to 61) during pregnancy and 60% (36 to 75) postpartum. In women vaccinated before 29 weeks gestational age, the estimated efficacy was 30% (-2 to 52), and in women vaccinated at or after 29 weeks, efficacy was 71% (50 to 83). Efficacy was similar in infants born to mothers vaccinated before or after 29 weeks gestation (34% [95% CI 12 to 51] vs 35% [11 to 52]). There was no overall association between maternal vaccination and low birthweight, stillbirth, preterm birth, and small for gestational age. At 6 months of age, the intervention and control groups were similar in terms of underweight (weight-for-age), stunted (length-for-age), and wasted (weight-for-length). Median centile change from birth to 6 months of age was similar between the intervention and the control groups for both weight and length. INTERPRETATION: The assessment of efficacy for women vaccinated before 29 weeks gestational age might have been underpowered, because the point estimate suggests that there might be efficacy despite wide CIs. Estimates of efficacy against PCR-confirmed influenza and safety in terms of adverse birth outcomes should be incorporated into any further consideration of maternal influenza immunisation recommendations. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Omer SB, Clark DR, Madhi SA, et al. Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. Lancet Respir Med. 2020. PMID: 32526188. doi:10.1016/S2213-2600(19)30479-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。